Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIRE: Assessing immune response after eribulin in advanced breast cancer
2020-001938-35Phase 4Terminated
- Sponsor
- Institut für Frauengesundheit
- Start
- Jul 2020
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of eribulin, paclitaxel, capecitabine and vinorelbine in breast cancer (2 arms), sponsored by Institut für Frauengesundheit. Primary endpoint: Immune responsiveness after chemotherapy. Started Jul 2020; status: terminated.
02
Drugs
eribulinpaclitaxelcapecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-001938-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001938-35.